Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a human amniotic mesenchymal stem cell

A kind of stem cell, human amniotic membrane technology, applied in the field of biomedicine, can solve the problems of human amniotic membrane mesenchymal stem cells, etc.

Active Publication Date: 2020-01-03
AFFILIATED HOSPITAL OF ZUNYI MEDICAL COLLEGE
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Mesenchymal stem cells currently used for research and treatment of myocardial ischemia are mainly derived from bone marrow and fat, but there is no report on the use of human amniotic mesenchymal stem cells to prepare corresponding therapeutic drugs in cardiopulmonary bypass myocardial reperfusion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a human amniotic mesenchymal stem cell
  • Application of a human amniotic mesenchymal stem cell
  • Application of a human amniotic mesenchymal stem cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0127] Application of human amniotic mesenchymal stem cells in the preparation of preparations for treating myocardial ischemia-reperfusion injury during cardiopulmonary bypass. The specific application method is: suspending human amniotic mesenchymal stem cells in physiological saline to prepare human amniotic mesenchymal stem cell injection, and then injecting it intravenously.

Embodiment 2

[0129] Application of human amniotic mesenchymal stem cells in the preparation of preparations for treating myocardial ischemia-reperfusion injury during cardiopulmonary bypass. The specific application method is: suspending human amniotic mesenchymal stem cells in physiological saline to prepare human amniotic mesenchymal stem cell injection, and then injecting it intravenously. Human amniotic mesenchymal stem cells are the 3rd to 5th passage cells obtained through subculture, and more than 90% of their cytoplasm express vimentin, and the expression of CD90, CD105, CD44 and CD73 is positive, and CD34, CD45, CD11b, CD19 and HLA-DR negative.

Embodiment 3

[0131] Application of human amniotic mesenchymal stem cells in the preparation of preparations for treating myocardial ischemia-reperfusion injury during cardiopulmonary bypass. The specific application method is: suspending human amniotic mesenchymal stem cells in physiological saline to prepare human amniotic mesenchymal stem cell injection, and then intravenously injecting it through the femoral vein. Human amniotic mesenchymal stem cells are cultured according to the method described in the invention patent No. 2011100809686. They are the 3rd to 5th generation human amniotic mesenchymal stem cells obtained through subculture, and more than 90% of their cytoplasm express vimentin, and Expression of CD90, CD105, CD44, and CD73 was positive, and CD34, CD45, CD11b, CD19, and HLA-DR were negative.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of human amniotic mesenchymal stem cells in preparation of a preparation for treating a myocardial ischemia reperfusion injury generated after cardiopulmonary bypass.In the myocardial ischemia reperfusion process after the cardiopulmonary bypass, the human amniotic mesenchymal stem cells can effectively prevent myocardial cells from being injured in myocardial ischemia reperfusion, obviously improve the cardiac functions, lower the levels of myocardial injury specific marker protein lactic dehydrogenase, creatine kinase isoenzyme and troponin I, lower the levels of a plasma inflammatory factor interleukin-8 and a tumor mecrosis factor-alpha, increase the content of the plasma inflammatory factor interleukin-10, obviously improve pathological changes of the myocardial tissue, reduce myocardial cell apoptosis, lower the expression level of cell apoptosis promoting protein, increase the expression quantity of anti-apoptoasis protein and can protect the functions of myocardial cell mitochondria.By preparing the human amniotic mesenchymal stem cells into an injection for treatment on the myocardial ischemia reperfusion injury generated after the cardiopulmonary bypass, the cardiac functions can be effectively protected, and postoperative complications of the cardiopulmonary bypass are relieved.

Description

technical field [0001] The invention relates to an application of human amniotic mesenchymal stem cells, belonging to the technical field of biomedicine. Background technique [0002] According to the statistical data of "China Cardiovascular Disease Report" in 2010, there are about 7.5 million people in my country who need cardiac surgery due to various heart diseases, including more than 3 million for coronary heart disease, more than 2.5 million for rheumatic heart disease, and more than 2 million for congenital heart disease. million, 200,000 new cases of congenital heart disease each year. Cardiopulmonary bypass (CPB) is one of the necessary techniques for open-heart surgery. However, a series of complications caused by myocardial ischemia reperfusion injury (MIRI) after cardiopulmonary bypass is still the main cause of high mortality. [0003] Extracorporeal circulation refers to the whole process of connecting the large blood vessels of the human body with an artific...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/0775A61P9/10
CPCA61K35/28C12N5/0668
Inventor 梁贵友余丽梅巫宏坤强勇刘达兴张登沈
Owner AFFILIATED HOSPITAL OF ZUNYI MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com